Page 3 - கவின் ஸ்பென்சர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கவின் ஸ்பென்சர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கவின் ஸ்பென்சர் Today - Breaking & Trending Today

U.S. Patents for Nicox's Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension Paris Stock Exchange:COX

and
for future
value as we continue the development of our clinical assets NCX 470 in glaucoma and NCX 4251 in blepharitis.”
Latanoprostene bunod, the pharmaceutical active ingredient in VYZULTA, was invented and patented by Nicox, and is the first product from the company’s proprietary nitric oxide-donating research platform to be approved for commercialization. Under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the “Hatch-Waxman Act”) certain patents for pharmaceutical products in the U.S. may be extended by up to 5 years once product approval from the FDA has been obtained. ....

New York , United States , Provence Alpes Côd Azur , Hong Kong , France General , United Kingdom , City Of , South Korea , Victor Floc H , Gavin Spencer , Yi Chen , Nicox Latanoprostene Bunod , Damien Choplain , Pharma Bio , Mary Ann Chang , Pooya Hemami , Sophia Antipolis , Sophie Baumont , Michele Garufi , Louise Chen , Kepler Cheuvreux , States Europe , Lifesci Advisors , Garnier Co , Drug Administration , Trademark Office ,

Nicox Provides First Quarter 2021 Business Update and Financial Highlights

Nicox Provides First Quarter 2021 Business Update and Financial Highlights
NCX 470 Phase 3 trials in glaucoma on track for top-line results
in
top-line
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q1 2021 for Nicox SA and its subsidiaries (the Nicox Group ), and updated key expected value-inflection milestones.
Key Expected Milestones
program in glaucoma
: Nicox s lead clinical product candidate, NCX 470, is a novel nitric oxide (NO)-donating prostaglandin analog currently in two multi-regional Phase 3 trials for the evaluation of the safety and efficacy of NCX 470 ophthalmic solution, 0.1%, against latanoprost ophthalmic solution, 0.005%, for lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Top-line results are currently expected in Q2 2022 for Mont Blanc and in Q4 202 ....

New York , United States , Provence Alpes Côd Azur , Hong Kong , France General , United Kingdom , South Korea , Gavin Spencer , Kepler Cheuvreux Damien Choplain , Mary Ann Chang , Pharma Bio , Mont Blanc , Sophia Antipolis , Sophie Baumont , Cantor Fitzgerald Louise Chen , States Europe , Garnier Co Victor Floch Paris , Nicox Group , Lifesci Advisors , Head Of Corporate Development , Eyevance Pharmaceuticals , Edison Investment Research Pooya Hemami London , Hikma Pharmaceuticals , China Center , Provides First Quarter , Euronext Paris ,

Nicox Provides First Quarter 2021 Business Update and Financial Highlights

Nicox Provides First Quarter 2021 Business Update and Financial Highlights
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Provence Alpes Côd Azur , Hong Kong , France General , United Kingdom , City Of , South Korea , Yi Chen , Victor Floch , Gavin Spencer , Mary Ann Chang , Damien Choplain , Pharma Bio , Pooya Hemami , Mont Blanc , Sophia Antipolis , Sophie Baumont , Louise Chen , Kepler Cheuvreux , States Europe , Nicox Group , Lifesci Advisors , Garnier Co , Head Of Corporate Development , Edison Investment Research ,

BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL

IS NOW APPROVED IN BRAZIL
SOPHIA ANTIPOLIS, France, and LAVAL, Quebec, April 16, 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária).
VYZULTA is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.
1
“The approval of VYZULTA in Brazil marks its tenth regulatory approval. We will continue to focus our efforts on securing additional regulatory approvals for this important treatment option for people suffering from glaucoma to he ....

United States , Hong Kong , Nova Scotia , South Korea , Thomasj Appio , Gavin Spencer , Lainie Keller , Pharma Bio , Mary Ann Chang , Sophia Antipolis , Sophie Baumont , Bausch Health Companies Inc , Lomb International , Bausch Health Investor Contact , Exchange Commission , Brazilian Health Regulatory Agency , Bausch Health Media Contact , Bausch Lomb Incorporated , Eyevance Pharmaceuticals , Bausch Health , Media Contact , Media France Contact , Health Investor Contact , Health Media Contact , Bausch Health Companies , Euronext Paris ,

Nicox Announces 2020 Financial Results and 2021 Key Milestones

Nicox Announces 2020 Financial Results and 2021 Key Milestones
Nachrichtenquelle: globenewswire
| 01.03.2021, 07:30 |
127
Net revenue
Cash position increased to €47.2 million as of December 31, 2020March 1
st, 2021 – release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the financial and operating results for Nicox and its subsidiaries (the
“Nicox Group”) for the year ended December 31, 2020, as approved by the Board of Directors on February 26, 2021, and provided upcoming 2021 key milestones.
2020 Financial Summary
Net revenue
1 for the full year 2020 was €12.9 million (€2.4 million in net royalties, €10.5 million in license payments), compared to €6.9 million (€2.1 million in net royalties,
€4.8 million in upfront an ....

New York , United States , Provence Alpes Côd Azur , Hong Kong , France General , United Kingdom , City Of , South Korea , Yi Chen , Victor Floc H , Gavin Spencer , Mary Ann Chang , Damien Choplain , Pharma Bio , Diesen Artikel , Mont Blanc , Sophia Antipolis , Sophie Baumont , Louise Chen , Kepler Cheuvreux , States Europe , Nicox Group , Edison Investment Research Pooya Hemami , Lifesci Advisors , Garnier Co , Head Of Corporate Development ,